Interim report Period from January 2016 to September 2016
2016 THIRD QUARTER (Jul-Sep) · Operating loss KSEK -1,983 (-2,683) · Loss per share SEK -0.10 (-0.28) FIRST NINE MONTHS 2016 (Jan-Sep) · Operating loss KSEK -8,304 (-9,190) · Loss per share SEK -0.40 (-0.97) IMPORTANT EVENTS DURING THE PERIOD · Mr Hans von Celsing was elected as new Chairman of the Board and Mr Arne Ferstad as Board member in May and July, respectively. · On the 3rd of May, the first patients entered Peptonic Medical´s clinical phase 2b study. The aim of the study is to investigate the effect of Peptonic Medical’s product candidate